medigraphic.com
ISSN 2007-5294 (Print)
Confederación Nacional de Pediatría de México, A. C. (CONAPEME)

2012, Number 4

<< Back Next >>

Pediatr Mex 2012; 14 (4)

Clinical and immunophenotypic characteristics in a group of children with lymphoblastic acute leukemia

Quero-Hernández A, Estrada CR, Pacheco PI, Reyes GU, Álvarez Solís RM, Vargas VM

Language: Spanish
References: 28
Page: 166-171
PDF size: 39.99 Kb.


ABSTRACT

Introduction: The Acute Lymphoblastic Leukemia is the principle malignant neoplasia in children and it is a heterogeneous disorder, because of its clinical, morphological, immunophenotypic and cytogenetic characteristics. The objectives were to assess the distribution and frequency of immunophenotypic and clinical features in a group of pediatric patients. Material and methods: 110 patients were analyzed, both genders, and children under 15 years old with immunophenotypic diagnosis of Lymphoblastic Acute Leukemia. Results: The average age was of 7.7 years old, the average leukocyte count was of 56,100/mm3, bone pain was present in 75% of the cases and the highest degree of infiltration was observed in the T cells. The frequency of ALL Pre-B common or CD10+ was of 92%, Pre-B CD10- (1.8%), B cells (1.8%), T cells (6.4%) and biphenotypic (2.7%) and myeloid aberrancy occurred in greater proportion in group pre-B common. Conclusion: The initial clinical manifestation in this study group was bone pain; the mean age at diagnosis was higher than the national average, well as the presence of hyperleukocytosis. Immunophenotypic characteristics of the diverse pre-B predominated common, which differs from previous reports.


REFERENCES

  1. Rivera-Luna R, Leal-Leal C, Cárdenas-Cardós R. A survey of 4,706 children with cancer. Certain aspects epidemiological from a single institution. Bol Med Hosp Infant Mex 1996; 53: 598-604.

  2. Quero-Hernández A, Coronado-Díaz R, Pérez-Bautista A, Gómez-Reyes U. Neoplasias malignas en niños en dos hospitales de Oaxaca, México (1996-2002). Acta Pediatr Mex 2006; 27: 183-189.

  3. Zahid C, Crawford E, Pathan H, Jasper L, Covinsky MA, Johnson LR, White G. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003; 127: 42-48.

  4. Uckun FM, Sensel M, Sun L, Steinherz P, Trigg M, Heerema N, Sather H et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91 (3): 735-746.

  5. Craig FE, Foon K. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941-3967.

  6. Niemeyer MC, Sallan ES. Acute lymphoblastic leukemia. In: Nathan GD, Orkin HS. Editors. Hematology of infancy and childhood. Philadelphia: Saunders1998; (2): 1245-1285.

  7. Ching-Hon Pui, Frederick GB, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82 (15): 343-362.

  8. Hann IM, Richards SM, Eden OB, Hill FG. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukemia trial XI (MRC UKALLXI) Medical Research Council Childhood Leukemia Working Party. Leukemia 1998; 12 (8): 1249-1255.

  9. Ludwing WD, Teichmann JV, Sperling C, Komischke B, Ritter J, Reiter A, Odenwald E, Sauter S, Riehm H. Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (LAL) in children: experiences of the ALL-BFM83 and 86 studies. Klin Padiatr 1990; 202 (4): 243-252.

  10. Paredes-Aguilera R, Romero-Guzmán, López-Santiago N, Bravo-Lindoro A, Correa-González C, Joly-Linero R, Nieto-Martínez S, del Campo-Martínez A. Inmunofenotipificación de la leucemia aguda linfoblástica en niños mexicanos. Sangre 1999; 44 (3): 188-194.

  11. Wehermann TM, Kaiserling E, Horny HP. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. J Clin Pathol 1999; 52: 688-692.

  12. Basso G, Buldini B, De Zen L, Orfao A. New methodology approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675-692.

  13. Jennings D, Foon K. Recent advances in flow cytometry: application to the diagnosis of hematology malignancy. Blood 1997; (90): 2863-2892.

  14. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3942-3967.

  15. Ruiz-Argüelles A, Duque RE, Orfao A. Report on the first Latin American consensus conference for flow cytometric immunophenotyping of leukemia. Cytometry 1998; 34: 39-42.

  16. Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry 2005; 708: 39-44.

  17. Paredes AR, Romero GL, López SN, Burbano CL, Camacho MO, Nieto MS. Flow cytometric analysis of cell-surface and intracellular antigens in the Diagnosis of Acute Leukemia. American Journal of Hematology 2001; 68: 69-74.

  18. Ríos RB, Ortega AM, Pérez SM, Medina ANF, Del Campo MM, Rodríguez ZM, Montero PI et al. J Pediatr Hematol Oncol 2008; 30 (3): 199-203.

  19. Hann IM, Richards SM, Eden OB, Hill FG. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia 1998; 12 (8): 1249-1255.

  20. Seegmiller AC, Steven HK, Nitin JK, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol 2009; 132: 940-949.

  21. Khalidi HS, Chang KL, Medeiros LJ, Brynes RK, Slovak ML, Murata JL et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111 (4): 467-476.

  22. Sugss JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell Leukemias. Exp Mol Pathol 2007; 83 (3): 471-473.

  23. Pui CH, Behem FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82 (3): 342-362.

  24. Maman E, Steinberg DM, Batia SA, Izraeli A, Wientroub S. Acute lymphoblastic leukemia in children: correlation of musculoskeletal manifestations and immunophenotypes. J Child Orthop 2007; 1: 63-68.

  25. Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004; 22: 1215-1221.

  26. Kai T, Ishii E, Matsuzaki A, Okamura J, Ikuno Y, Tasaka et al. Clinical and prognostic implications of bone lesions in childhood leukemia at diagnosis. 1996; 23 (1): 119-123.

  27. Ricke AM, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2,169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.

  28. Margolin J, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Third Edition. New York: Lippincott-Raven; 409-462.




2020     |     www.medigraphic.com